These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33019339)

  • 1. Dyskinesia Severity Estimation in Patients with Parkinson's Disease Using Wearable Sensors and A Deep LSTM Network.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():6001-6004. PubMed ID: 33019339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyskinesia estimation during activities of daily living using wearable motion sensors and deep recurrent networks.
    Hssayeni MD; Jimenez-Shahed J; Burack MA; Ghoraani B
    Sci Rep; 2021 Apr; 11(1):7865. PubMed ID: 33846387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motion sensor dyskinesia assessment during activities of daily living.
    Pulliam CL; Burack MA; Heldman DA; Giuffrida JP; Mera TO
    J Parkinsons Dis; 2014; 4(4):609-15. PubMed ID: 25208729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous Assessment of Levodopa Response in Parkinson's Disease Using Wearable Motion Sensors.
    Pulliam CL; Heldman DA; Brokaw EB; Mera TO; Mari ZK; Burack MA
    IEEE Trans Biomed Eng; 2018 Jan; 65(1):159-164. PubMed ID: 28459677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel method for assessing the severity of levodopa-induced dyskinesia using wearable sensors.
    Lee SI; Daneault JF; Golabchi FN; Patel S; Paganoni S; Shih L; Bonato P
    Annu Int Conf IEEE Eng Med Biol Soc; 2015 Aug; 2015():8087-90. PubMed ID: 26738170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic-induced dyskinesia assessment based on a single belt-worn accelerometer.
    Pérez-López C; Samà A; Rodríguez-Martín D; Moreno-Aróstegui JM; Cabestany J; Bayes A; Mestre B; Alcaine S; Quispe P; Laighin GÓ; Sweeney D; Quinlan LR; Counihan TJ; Browne P; Annicchiarico R; Costa A; Lewy H; Rodríguez-Molinero A
    Artif Intell Med; 2016 Feb; 67():47-56. PubMed ID: 26831150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objective motion sensor assessment highly correlated with scores of global levodopa-induced dyskinesia in Parkinson's disease.
    Mera TO; Burack MA; Giuffrida JP
    J Parkinsons Dis; 2013 Jan; 3(3):399-407. PubMed ID: 23948993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early morning off-medication dyskinesias, dystonia, and choreic subtypes.
    Cubo E; Gracies JM; Benabou R; Olanow CW; Raman R; Leurgans S; Goetz CG
    Arch Neurol; 2001 Sep; 58(9):1379-82. PubMed ID: 11559308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of levodopa-induced dyskinesia using automated motion sensing technology.
    Mera TO; Burack MA; Giuffrida JP
    Annu Int Conf IEEE Eng Med Biol Soc; 2012; 2012():154-7. PubMed ID: 23365855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2001; (1):CD001516. PubMed ID: 11279718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole for levodopa-induced complications in Parkinson's disease.
    Clarke CE; Deane KH
    Cochrane Database Syst Rev; 2000; (3):CD001516. PubMed ID: 10908503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of dyskinesias with L-dopa infusion in advanced Parkinson's disease.
    Timpka J; Fox T; Fox K; Honig H; Odin P; Martinez-Martin P; Antonini A; Chaudhuri KR
    Acta Neurol Scand; 2016 Jun; 133(6):451-8. PubMed ID: 26358227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study.
    Péchevis M; Clarke CE; Vieregge P; Khoshnood B; Deschaseaux-Voinet C; Berdeaux G; Ziegler M;
    Eur J Neurol; 2005 Dec; 12(12):956-63. PubMed ID: 16324089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.